Operating as the manufacturing center of healthcare brand Orzax, Nuvita İlaç achieved measurable gains in the 2025 edition of the Turkey R&D 500 Survey, conducted annually by the business publication Turkishtime. Compiled from public disclosures, Ministry-accredited R&D centers, and leading exporter metrics, the survey benchmarks corporate innovation capital across the country.
53.8% Growth in R&D Expenditure to TL 84.8 Million
Key operational metrics regarding Nuvita İlaç’s research and project footprint include:
Expenditure Rankings: Advanced 17 positions year-on-year from 248th to 231st place, securing its position among Turkey’s top 250 investing enterprises.
Investment Volume: Annual R&D expenditures grew by 53.8%, reaching TL 84.8 million.
Project Volume Expansion: The number of active research projects increased from 38 to 49—a 28.9% rise. This elevated the company 24 places from 65th to 41st position nationwide, entering the top 50 corporate leaders in total project volume.
Statement from R&D Manager Akif Emre Kavak
Akif Emre Kavak, R&D Manager at Nuvita İlaç, stated:
We regard R&D as an essential pillar of our sustainable growth and high-value manufacturing vision. By combining scientific knowledge with our production competencies, our projects contribute both to our industry's advancement and the national R&D ecosystem. Through innovative programs run at our R&D center, we introduce new product and manufacturing solutions while deepening capabilities in strategic raw materials. Looking ahead, we will continue investing in science and innovation to deliver high-value solutions that support human health.
